ITALY – Stevanato Group, an Italian provider of drug containment, drug delivery, and diagnostic solutions has partnered with Recipharm on pre-fillable syringes for soft mist inhaler.
Under the collaboration, Stevanato Group will offer and produce its glass pre-fillable syringe Alba assembled with the Integrated Spray Module (ISM) of Recipharm’s soft mist inhaler technology, the Pre-Filled Syringe Inhaler (PFSI).
The partnership shows Stevanato’s strengths as a one-stop shop that provides support for contract drug manufacturing companies’ drug development programs from the clinical stage to market release.
Stevanato said that its Alba syringes include an internal coating based on silicone oil that is cross-linked with the glass surface to minimize sub-visible particle release and ensure better performance during delivery.
The Alba syringe together with Recipharm’s soft mist inhaler technology will deliver sensitive medication items more effectively to the respiratory airways, offering biopharma firms a containment solution with improved stability and safety.
Under the deal, Stevanato will assume responsibility for the overall primary drug packaging, while CDMO will focus on the design and production of the spray technology, the inhalation device, and the fill and finish of the product.
Stevanato Group CEO Franco Moro said: “Creating a network of strategic collaboration partners is an important element of our long-term strategy to match customers’ needs and address self-administration trends in patient care with user-friendly drug delivery devices that provide variable and accurate dosing.
“This agreement marks another key step in broadening our high-value solutions and integrated capabilities as we continue to diversify and enhance our presence in the drug delivery market of pen injectors, auto-injectors, inhalers, and wearable pods.”
Sustainable growth funding
Meanwhile, Stevanato Group earlier this month secured €130 million (US$138.89m) ESG-Linked financing from BNL BNP Paribas and Cassa Depositi e Prestiti to support sustainable global growth.
BNL BNP Paribas has contributed €70 million (US$74.79 m)which is tied to two ESG-related objectives including increasing the company’s renewable-based energy and waste management improvements.
An additional €60 million (US$64.10m) is being financed by CDP to be allocated to new investments in technological innovation, the purchase of state-of-the-art machinery, and the modernization of a production plant in Italy, which may also potentially generate positive employment effects.
The financing agreements help solidify Stevenato’s commitment to organic and sustainable growth. The Company’s ongoing investments in the United States, Italy and China will expand regional production and meet the rising global demand for high-performance drug containment solutions.
For all the latest packaging and printing industry news from Africa and the World, subscribe to our NEWSLETTER, follow us on Twitter and LinkedIn, like us on Facebook, and subscribe to our YouTube channel.